louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02023034: Virtual Exercises in Patients With Parkinson's Disease.
Official title: EFFECTIVENESS OF VIRTUAL EXERCISES ON THE FUNCTIONAL EXERCISE CAPACITY, FATIGUE AND QUALITY OF LIFE IN PATIENTS WITH PARKINSON'S DISEASE: A RANDOMIZED CLINICAL TRIAL
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Parkinson Disease
Keywords: Parkinson disease, Physical Therapy, Fatigue, Quality of Life
Lead sponsor: Faculdade Evangelica do Parana
Sponsor class: OTHER
First posted: 2013-12-30
Enrollment: 20
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Introduction: Although the motor changes are well determined in Parkinson's disease (PD), few studies describe the effects the virtual exercises on the clinical and functional outcomes in this disease.

Objectives: To analyze the effectiveness of virtual exercises on functional exercise capacity, fatigue and quality of life in patients with PD.

Methods: 20 subjects, 60 years old will be included, who will be randomized into 2 groups: group of virtual exercises associated with conventional exercises (n = 10) and control group with conventional exercise group (n = 10).

The following variables are evaluated: functional exercise through walking test in 6 minutes, fatigue by the Fatigue Severity Scale and Quality of Life through Quality of Life Questionnaire-PDQ-39.


Eligibility criteria: Inclusion Criteria:

* will be selected for the study
* subjects with a clinical diagnosis of Parkinson's disease
* 0-III H\&Y
* 40 to 80 years
* both sexes
* with preserved cognitive stage (Mini Mental\> 24).

Exclusion Criteria:

* will be excluded subjects who have some acute pain or associated diseases
* such as severe or unstable heart disease
* visual disturbances
* using some march auxiliary device, which compromise the 6MWT and exercise protocol

Primary outcomes:
measure: Improvement of functional exercise capacity
timeFrame: The subjects will be followed for a period of 90 days.
Secondary outcomes:
measure: Reduction of Fatigue
timeFrame: The subjects will be followed for a period of 90 days.
Other outcomes:
measure: Improvement of Quality of life
timeFrame: The subjects will be followed for a period of 90 days.
Locations:
city: Curitiba
country: Brazil
facility: Associação Paranaense dos Portadores de Parkinsonismo
state: Parana
Study officials:
affiliation: Faculdade Evangelica do Parana
name: Silvia Valderramas, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00079534: Distant Healing for HIV/AIDS
Official title: Distant Healing Efforts for AIDS by Nurses and "Healers"
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV Infections
AIDS
Keywords: AIDS
HIV
Prayer
Healing
Complementary Therapies
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH)
Sponsor class: NIH
First posted: 2004-03-10
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether individuals praying at a distance (also known as "Distant Healing") can positively affect the health of people with HIV/AIDS.

Detailed description: Significant numbers of people with HIV/AIDS seek spiritual or "psychic" treatment. Distant healing could potentially be of benefit to large numbers of HIV/AIDS patients, as it is widely available and requires no travel or other activity on the part of the patient. However, the treatment can be costly and has not yet been proven effective in a controlled clinical trial. This study will evaluate the efficacy of distant healing in patients with HIV/AIDS.

Participants in this study will be randomly assigned to either the distant healing group or a control group. All participants will have hour-long study visits at entry and Months 6 and 12. At study visits, participants will complete a demographic questionnaire, self-report health and symptom inventory, quality of life assessment, and profile of mood states. Blood will be drawn at each study visit.

Eligibility criteria: Inclusion criteria

* HIV infection
* History of a CD4 cell count less than 200 cells/mm3
* Stable antiretroviral regimen
* English-speaking

Exclusion criteria

* Inability or unwillingness to fill out questionnaires
* History of non-HIV related life-threatening disease

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: California Pacific Medical Center
state: California
Study officials:
affiliation: University of California, San Francisco
name: Donald Abrams, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: California Pacific Medical Center
name: Jerome J. Stone, MA, RN
role: STUDY_DIRECTOR
References:
Clinical trial NCT02645734: The Effect of Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema
Official title: The Comparison Between the Therapeutic Effect of Intravitreal Bevacizumab and Ziv-aflibercept in Diabetic Macular Edema
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Diabetic Macular Edema
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
First posted: 2016-01-05
Enrollment: 133
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this double clinical trial 132 patient with the history of DME (Diabetic Macular Edema) to receive intravitreous bevacizumab at a dose of 1.25mg (44 patient) , ziv-aflibercept at dose of 1.25 mg (44 patient) , ziv-aflibercept at dose of 2.5 mg (44 patient) .

The study drugs were administered as often as every 4 weeks for 3 months.monitoring of best-corrected visual acuity, CST ( Central Subfield Thickness) by OCT (Optical coherence tomography) was done from base line ,4 weeks, 8weeks after injection.


Eligibility criteria: Inclusion Criteria:

* The patient at least 18 years old had type 1 or 2 diabetes who presented with Central DME involvement (defined as retinal thickening involving 1mm central sub field thickness(CCT)
* Have at least a BCVA ( best corrected visual acuity) between 20/50 to 20/320 Snellen equivalent
* Have received to anti-VEGF( anti -vascular endothelial growth factor) and laser treatment within the previous 3 months

Exclusion Criteria:

* Uncontrolled glaucoma/uncontrolled diabet , high risk PRP(pan-retinal photocoagulation), one eye
* Prior treatment with intravitreal or peribulbar injection and laser therapy during the last 3 months
* Substantial cataract, history of uveitis
* Macular edema due to a cause other than DME
* VMT(Vitreomacular traction ) and ERM (epiretinal membrane)

Primary outcomes:
measure: visual acuity
timeFrame: until 6 month
Secondary outcomes:
measure: central subfield thickness(CCT)
timeFrame: until 6 month
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Islamic Republic of Iran
Study officials:
References:
Clinical trial NCT03328234: Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03
Official title: A Randomized Phase III Study of Simultaneous Integrated Boost Intensity Modulated Radiation Therapy (SIB-IMRT) With or Without Concurrent Chemotherapy Followed by Consolidation Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG-P03
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: IMRT With or Without Concurrent Chemotherapy for Esophageal Cancer
Lead sponsor: ChineseAMS
Sponsor class: UNKNOWN
First posted: 2017-11-01
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The investigators aimed to compare elective nodal irradiation versus involved field irradiation with or without concurrent chemotherapy and the addition of consolidation chemotherapy for patients with extensive lymphatic metastasis of esophageal cancer.


Eligibility criteria: Inclusion Criteria:

* Age\<70
* Diagnosis of clinical stage T2-4N0-1M1（According to UICC 2002）
* A untreated squamous esophageal carcinoma
* Karnofsky performance status(KPS)≥ 70 and Charlson score ≤3
* Adequate organ function
* No known history of drug allergy
* Blood routine examination : WBC≥4.0
* hepatic and renal function are normal

Exclusion Criteria:

* Age≥ 70 or ≤ 16
* Already received the treatment of chemotherapy or radiotherapy
* Pregnant or lactating females
* Known drug allergy
* Without agreement of informed consent form
* Insufficient hepatorenal function or Blood routine examination
* Severe cardiovascular diseases, diabetes with uncontrolled blood sugar, mental disorders, uncontrolled severe infection, active ulceration which need intervention.

Primary outcomes:
measure: Overall survival (OS)
timeFrame: 1 year
measure: Overall survival (OS)
timeFrame: 2 year
measure: Overall survival (OS)
timeFrame: 3 year
Secondary outcomes:
measure: Progression-free survival (PFS)
timeFrame: 1 year
measure: Progression-free survival (PFS)
timeFrame: 2 year
measure: Progression-free survival (PFS)
timeFrame: 3 year
measure: Local recurrence-free rate（LRFS）
timeFrame: 1 year
measure: Local recurrence-free rate（LRFS）
timeFrame: 2 year
measure: Local recurrence-free rate（LRFS）
timeFrame: 3 year
measure: Completion Rate
timeFrame: up to 2 year
measure: Adverse events
timeFrame: up to 5 year
Other outcomes:
Locations:
city: Beijing
country: China
facility: Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
Study officials:
References:
Clinical trial NCT02383134: Maximal Distance for Successful Supraclavicular Block
Official title: The Maximum Effective Needle-to-Nerve Distance for Anesthetic Ultrasound-Guided Supraclavicular Brachial Plexus Block
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Regional Anesthesia
Ultrasound
Supraclavicular Block
Lead sponsor: Tunisian Military Hospital
Sponsor class: OTHER
First posted: 2015-03-09
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing upper limb surgery surgery (hand, forearm, elbow)

Brief summary: The achievement of peripheral nerve block requires several needle passes, with each of them being at risk of causing nerve injury either by direct trauma or intraneural injection even with the use of the ultrasound.

The ultrasound guided supraclavicular brachial plexus block is known to be at risk of pneumothorax and / or nerve injury.

This study is designed to determine the maximal effective distance away from the nerve for the injection to be effective.


Eligibility criteria: Inclusion Criteria:

* ASA physical status I-III
* 18-85 years of age, inclusive
* surgery less than 3 hours

Exclusion Criteria:

* contraindications to brachial plexus block (e.g., allergy to local anesthetics, coagulopathy, malignancy or infection in the area)
* existing neurological deficit in the area to be blocked
* pregnancy
* history of neck surgery or radiotherapy
* inability to understand the informed consent and demands of the study

Primary outcomes:
measure: Success of the ultrasound guided supraclavicular block at 30 minutes after injection at a specific distance of the needle tip from the outer sheeth of the nerve
timeFrame: 30 minutes
Secondary outcomes:
measure: •The onset time of sensory and motor block
timeFrame: the block success will be assessed for each patient every 5 min for 30 mins in the operating room beginning when the needle exits the skin
measure: The proportion of inadequate and failed blocks.
timeFrame: the block success will be assessed for each patient every 5 min for 30 mins in the operating room beginning when the needle exits the skin
measure: The presence of other complications such as hematoma, infection, pneumothorax.
timeFrame: up to 48 hours post operative.
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02065934: Clinical Audit of Cardio Pulmonary Resuscitation Management in Adults Patient Units of Care by in Situ Simulation
Official title: Clinical Audit of Cardio Pulmonary Resuscitation Management in Adults Patient Units of Care by in Situ Simulation
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: in Hospital Cardiac Arrest
in Situ Simulation
Clinical Audit
Education
Keywords: in hospital cardiac arrest
in situ simulation
clinical audit
education
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2014-02-19
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Team members

Brief summary: Clinical audit of in-hospital cardiac arrest management by in situ simulation

Objectives: correct latent safety threats, knowledge gap, and crisis resource management (CRM)

Design: clinical audit, observational sudy. Primary outcome: In Hospital resuscitation scale. Exploratory outcomes: non technical skills, validated stress inventory, and questionnaire on perceptions of the simulation and organisational changes needed.


Eligibility criteria: Inclusion Criteria:

* team members: nurses, auxiliary nurses, residents, doctors, students

Exclusion Criteria:

* non volunteers

Primary outcomes:
measure: In-Hospital resuscitation scale
timeFrame: 5 months
Secondary outcomes:
measure: ANTS scale
timeFrame: 5 months
measure: Peritraumatic Dissociative Experiences Questionnaire (PDEQ)
timeFrame: 5 months
measure: Peritraumatic Distress Inventory (PDI)
timeFrame: 5 months
Other outcomes:
Locations:
city: Besancon
country: France
facility: CHU Besancon
state: Doubs
Study officials:
affiliation: Centre Hospitalier Universitaire de Besancon
name: Yannick BRUNIN, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05471934: Satisfaction Survey - Cicaplast Mains
Official title: Satisfaction Survey - Cicaplast Mains
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hand Eczema
Hand Dermatoses
Lead sponsor: Cosmetique Active International
Sponsor class: INDUSTRY
First posted: 2022-07-25
Enrollment: 380
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population corresponds to hairdressing professionals who are in permanent contact with irritating products (e.g. shampoos, hair colorants, oxidants, ...).

Brief summary: The participants presenting with hand problems and meeting the inclusion criteria are asked to apply the study product for one month. They are evaluated before and after treatment.

Detailed description: The international, open, observational survey is conducted in 3 different countries.

Regarding the statistical analysis, the global satisfaction is described in 5 classes and in 2 classes "Satisfied + Very satisfied" vs. "Neither satisfied nor dissatisfied + Not so satisfied + Not at all satisfied". The 95% Confidence Interval (CI) of the percent of "Satisfied + Very satisfied" is also given.

On patients who already used cream at the inclusion, the following analyses are performed:

* Cross-tabulation between both visits,
* Test of the evolution between both visits using a special procedure for ordinal data with repeated measures,
* Description of a summary variable in 3 classes (Improved / No change / Worsened).

For the analysis of the hands problems, each sign is described at the inclusion and at the evaluation visit. The difference Evaluation-Inclusion is also given. The evolution of the sign is performed by a Wilcoxon test for matched samples.

Eligibility criteria: Inclusion Criteria:

* professionals that work on different activities related to hair in a beauty salon
* professionals presenting with current hand problems such as dryness, redness, irritations, cracks and fissures

Exclusion Criteria:

- professionals that do not meet the inclusion criteria

Primary outcomes:
measure: satisfaction rate
timeFrame: from baseline to Day28
Secondary outcomes:
measure: evaluation of hands problems (dryness, redness, irritations, cracks, fissures)
timeFrame: from baseline to Day28
Other outcomes:
Locations:
city: Roma
country: Italy
facility: Dermatology practices
city: Warsaw
country: Poland
facility: Dermatology practices
city: Ljubljana
country: Slovenia
facility: Dermatology practices
Study officials:
affiliation: Cosmetique Active International
name: Delphine Kerob
role: STUDY_DIRECTOR
References:
Clinical trial NCT04517734: Erythroferrone and Its Impact on Maternal and Neonatal Iron Homeostasis
Official title: Erythroferrone and Its Impact on Maternal and Neonatal Iron Homeostasis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pregnancy Anemia
Newborn; Anemia
Lead sponsor: Cornell University
Sponsor class: OTHER
Collaborators: name: University of California, Los Angeles
First posted: 2020-08-18
Enrollment: 338
Sex: FEMALE
Minimum age (years): 11
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pregnant women carrying multiple fetuses (twins, triplets and quadruplets) or pregnant adolescents carrying a single fetus

Brief summary: Erythroferrone (ERFE) is a recently identified iron-regulatory hormone that couples iron homeostasis to erythropoiesis but at this time there are no human data on this hormone in pregnant women and their neonates. The investigators hypothesize that ERFE is a sensitive biomarker of iron deficiency and anemia in pregnancy and neonates, and that it mediates the feedback mechanism to correct iron deficiency and anemia. To address this research gap, the investigators will measure ERFE in maternal serum, umbilical cord serum and placental tissue using an existing biospecimen archive.


Eligibility criteria: Inclusion Criteria:

* Healthy pregnant volunteers

Exclusion Criteria:

* Hemoglobinopathies
* Pre-existing diabetes
* Malabsorption diseases
* Pregnancy induced hypertension
* Elevated diastolic blood pressure (\>110)
* Previous treatment for lead exposure or elevated childhood lead concentrations.
* Preexisting medical conditions known to impact iron homeostasis

Primary outcomes:
measure: Maternal Erythroferrone During Pregnancy
timeFrame: Measures will be obtained from maternal blood collected throughout the 40 weeks of pregnancy
measure: Maternal Erythroferrone at Delivery
timeFrame: Measures will be obtained from maternal blood collected at delivery
measure: Neonatal Erythroferrone at Birth
timeFrame: Measures will be obtained from umbilical cord blood collected at delivery
measure: Placental Erythroferrone mRNA and Ferroportin protein Expression
timeFrame: Measures will be obtained from placental samples collected at delivery
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Rochester Adolescent Maternity Program
state: New York
city: Rochester
country: United States
facility: Strong Memorial Hospital
state: New York
Study officials:
affiliation: Cornell University
name: Kimberly O'Brien, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of California, Los Angeles
name: Elizabeta Nemeth, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Delaney KM, Guillet R, Pressman EK, Ganz T, Nemeth E, O'Brien KO. Serum Erythroferrone During Pregnancy Is Related to Erythropoietin but Does Not Predict the Risk of Anemia. J Nutr. 2021 Jul 1;151(7):1824-1833. doi: 10.1093/jn/nxab093.
Clinical trial NCT06684925: Stability and Function of Cervical Spine With Grade Point Average in University Students
Official title: Relationship Between Stability of Cervical Spine With Function and Grade Point Average in University Students
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Cervical Lesion
Lead sponsor: October 6 University
Sponsor class: OTHER
First posted: 2024-11-12
Enrollment: 124
Sex: ALL
Minimum age (years): 20
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CROSSOVER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A total of 124 students of both genders (42 males, 82 females) that agreed to participate, were recruited.

Brief summary: Spinal disorders are some of the most prevalent health concerns, especially among students

Detailed description: Stability of the cervical spine during head and cervical movements is an important component of cervical spine function .The deep neck flexor (DNF) (longus colli, longus capitis) muscles stabilize the neck and contribute to the control of head acceleration. Weakening of these muscles can lead to its coordination, activation, overload and poor support in the cervical structures. Further causes neck pain and altered neck position.

Studies conducted on patients with neck pain have also shown activation of these muscles and reduced resistance, associated disorders and headaches. Muscle resistance should be considered as a measure of neck function or injury.

University class, staying up late can be considered a risk factor for neck pain in students.

Eligibility criteria: Inclusion Criteria:

* Ages ranged from 20 to 25 years old
* Students have no health problems or complains

Exclusion Criteria:

* neck pain
* Cervical radiculopathy
* Fracture
* Previous back problems
* Students with low grade (GPA below 2)

Primary outcomes:
measure: Hand Held Dynamometer
timeFrame: Two months
measure: Neck disability index
timeFrame: Two months
Secondary outcomes:
Other outcomes:
Locations:
city: Amman
country: Jordan
facility: Al-Ahliyya Amman University
Study officials:
References: